TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.52
−1.05%Year over year
Reported trailing growth
- Revenue
- +121.5%
- EBITDA
- +18.5%
- EBIT
- +13.3%
- EPS
- +35.6%
- Free cash flow
- +3.3%
- Operating cash flow
- +2.9%
Forward estimates
Based on analyst estimates
- Revenue
- -88.5%
- EBITDA
- -78.2%
- EPS
- -72.4%
Three-year CAGR
- Revenue
- +35.9%
- EBITDA
- +22.2%
- EBIT
- +23.6%
- Net income
- +22.0%
- EPS
- +26.9%
- Free cash flow
- -5.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026